Please login to the form below

Not currently logged in
Email:
Password:

fasiglifam

This page shows the latest fasiglifam news and features for those working in and with pharma, biotech and healthcare.

Takeda drops prostate cancer drug in phase III

Takeda drops prostate cancer drug in phase III

The Japanese company also dropped diabetes candidate fasiglifam earlier this year, but it has a good crop of other products at, or nearing, commercialisation.

Latest news

  • Omontys terminal as Takeda switches off support Omontys terminal as Takeda switches off support

    Meanwhile, Takeda has had a bad run of luck with its late-stage pipeline of late, dropping diabetes candidate fasiglifam earlier this year.

  • Takeda pipeline hit by fasiglifam failure Takeda pipeline hit by fasiglifam failure

    Takeda pipeline hit by fasiglifam failure. Diabetes candidate had been set for a 2015 launch. ... Takeda has suffered a major pipeline setback after deciding to terminate development of fasiglifam, a candidate therapy for diabetes that had been scheduled

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics